Amsilarotene

Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with Ki of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer[1][2][3].

Product Specifications

CAS Number

[125973-56-0]

Product Name Alternative

TAC-101; Am 555S

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Apoptosis; RAR/RXR

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/amsilarotene.html

Concentration

10mM

Purity

99.67

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[Si](C)(C)C1=CC(C(NC2=CC=C(C(O)=O)C=C2)=O)=CC([Si](C)(C)C)=C1

Molecular Formula

C20H27NO3Si2

Molecular Weight

385.60

Precautions

H315, H319

References & Citations

[1]Sun SY, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res. 1997 Nov 1;57 (21) :4931-9.|[2]Suzuki N, et al. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma. Gynecol Oncol. 2004 Sep;94 (3) :643-9.|[3]Fujimoto K, et al. Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int J Cancer. 1999 May 17;81 (4) :637-44.